Advanced Proteome Therapeutics Corporation (APTCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | - USD | -100.0% |
| 2022 | 959.82 Thousand USD | 42.41% |
| 2021 | 673.96 Thousand USD | 18.25% |
| 2020 | 569.93 Thousand USD | -38.46% |
| 2019 | 926.08 Thousand USD | -15.77% |
| 2018 | 1.09 Million USD | 2.08% |
| 2017 | 1.07 Million USD | 27.4% |
| 2016 | 845.49 Thousand USD | -36.36% |
| 2015 | 1.32 Million USD | 29.29% |
| 2014 | 1.02 Million USD | -5.28% |
| 2013 | 1.08 Million USD | 18.63% |
| 2012 | 914.38 Thousand USD | -15.88% |
| 2011 | 1.08 Million USD | -5.35% |
| 2010 | 1.14 Million USD | -7.02% |
| 2009 | 1.23 Million USD | -17.04% |
| 2008 | 1.48 Million USD | -33.0% |
| 2007 | 2.22 Million USD | 190486.88% |
| 2006 | 1166.00 USD | -99.8% |
| 2005 | 590.13 Thousand USD | 2022.63% |
| 2004 | -30.69 Thousand USD | -164.33% |
| 2003 | 47.71 Thousand USD | -69.47% |
| 2002 | 156.26 Thousand USD | 131.79% |
| 2001 | 67.41 Thousand USD | -98.04% |
| 2000 | 3.43 Million USD | -24.05% |
| 1999 | 4.51 Million USD | 48.52% |
| 1998 | 3.04 Million USD | 67.78% |
| 1997 | 1.81 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2023 Q4 | - USD | -100.0% |
| 2023 Q2 | 286.69 Thousand USD | 11.85% |
| 2023 Q1 | 256.32 Thousand USD | -0.57% |
| 2023 FY | - USD | -100.0% |
| 2023 Q3 | 149.78 Thousand USD | -47.75% |
| 2022 Q2 | 263.74 Thousand USD | 30.48% |
| 2022 FY | 959.82 Thousand USD | 42.41% |
| 2022 Q4 | 257.79 Thousand USD | 9.16% |
| 2022 Q1 | 202.12 Thousand USD | 17.63% |
| 2022 Q3 | 236.16 Thousand USD | -10.46% |
| 2021 FY | 673.96 Thousand USD | 18.25% |
| 2021 Q1 | 122.04 Thousand USD | -28.79% |
| 2021 Q2 | 187.65 Thousand USD | 53.76% |
| 2021 Q3 | 192.43 Thousand USD | 2.54% |
| 2021 Q4 | 171.83 Thousand USD | -10.7% |
| 2020 Q1 | 117.96 Thousand USD | -57.14% |
| 2020 Q3 | 137.63 Thousand USD | -3.69% |
| 2020 FY | 569.93 Thousand USD | -38.46% |
| 2020 Q4 | 171.39 Thousand USD | 24.53% |
| 2020 Q2 | 142.9 Thousand USD | 21.14% |
| 2019 Q2 | 206.44 Thousand USD | -24.13% |
| 2019 FY | 926.08 Thousand USD | -15.77% |
| 2019 Q1 | 272.08 Thousand USD | 41.5% |
| 2019 Q4 | 275.23 Thousand USD | 59.72% |
| 2019 Q3 | 172.32 Thousand USD | -16.53% |
| 2018 Q2 | 298.86 Thousand USD | 9.73% |
| 2018 Q1 | 272.35 Thousand USD | -13.14% |
| 2018 Q4 | 192.28 Thousand USD | -42.78% |
| 2018 FY | 1.09 Million USD | 2.08% |
| 2018 Q3 | 336.02 Thousand USD | 12.44% |
| 2017 FY | 1.07 Million USD | 27.4% |
| 2017 Q4 | 313.53 Thousand USD | 1.81% |
| 2017 Q3 | 307.94 Thousand USD | 19.13% |
| 2017 Q2 | 258.5 Thousand USD | 31.1% |
| 2017 Q1 | 197.18 Thousand USD | -28.99% |
| 2016 Q2 | 208.95 Thousand USD | 23.24% |
| 2016 Q3 | 189.31 Thousand USD | -9.4% |
| 2016 Q4 | 277.66 Thousand USD | 46.67% |
| 2016 Q1 | 169.55 Thousand USD | -44.05% |
| 2016 FY | 845.49 Thousand USD | -36.36% |
| 2015 Q3 | 257.55 Thousand USD | -12.17% |
| 2015 Q1 | 474.59 Thousand USD | 58.84% |
| 2015 FY | 1.32 Million USD | 29.29% |
| 2015 Q2 | 293.25 Thousand USD | -38.21% |
| 2015 Q4 | 303.06 Thousand USD | 17.67% |
| 2014 Q2 | 237.77 Thousand USD | 1.77% |
| 2014 Q4 | 298.78 Thousand USD | 16.25% |
| 2014 Q1 | 233.62 Thousand USD | -13.75% |
| 2014 Q3 | 257.02 Thousand USD | 8.1% |
| 2014 FY | 1.02 Million USD | -5.28% |
| 2013 Q1 | 222.51 Thousand USD | -28.39% |
| 2013 Q4 | 270.86 Thousand USD | -7.89% |
| 2013 Q3 | 294.06 Thousand USD | 1.41% |
| 2013 Q2 | 289.97 Thousand USD | 30.32% |
| 2013 FY | 1.08 Million USD | 18.63% |
| 2012 FY | 914.38 Thousand USD | -15.88% |
| 2012 Q1 | 165.82 Thousand USD | -32.8% |
| 2012 Q2 | 196.14 Thousand USD | 18.28% |
| 2012 Q3 | 241.68 Thousand USD | 23.22% |
| 2012 Q4 | 310.73 Thousand USD | 28.57% |
| 2011 Q4 | 246.77 Thousand USD | -18.35% |
| 2011 FY | 1.08 Million USD | -5.35% |
| 2011 Q3 | 302.23 Thousand USD | 9.6% |
| 2011 Q2 | 275.74 Thousand USD | 5.16% |
| 2011 Q1 | 262.2 Thousand USD | 46.17% |
| 2010 Q1 | 416.35 Thousand USD | 46.05% |
| 2010 Q3 | 263.57 Thousand USD | -8.92% |
| 2010 Q4 | 179.38 Thousand USD | -31.94% |
| 2010 FY | 1.14 Million USD | -7.02% |
| 2010 Q2 | 289.39 Thousand USD | -30.49% |
| 2009 Q2 | 305.34 Thousand USD | -12.6% |
| 2009 FY | 1.23 Million USD | -17.04% |
| 2009 Q3 | 295.23 Thousand USD | -3.31% |
| 2009 Q4 | 285.07 Thousand USD | -3.44% |
| 2009 Q1 | 349.37 Thousand USD | -2.2% |
| 2008 Q4 | 357.23 Thousand USD | -9.92% |
| 2008 Q1 | 371.94 Thousand USD | -74.71% |
| 2008 Q3 | 396.55 Thousand USD | 9.21% |
| 2008 Q2 | 363.11 Thousand USD | -2.37% |
| 2008 FY | 1.48 Million USD | -33.0% |
| 2007 Q2 | 173.95 Thousand USD | 133.42% |
| 2007 Q1 | 74.52 Thousand USD | 156.43% |
| 2007 FY | 2.22 Million USD | 190486.88% |
| 2007 Q4 | 1.47 Million USD | 192.52% |
| 2007 Q3 | 502.84 Thousand USD | 189.06% |
| 2006 Q4 | -132.06 Thousand USD | -320.56% |
| 2006 Q2 | 52.53 Thousand USD | 85.7% |
| 2006 Q1 | 28.28 Thousand USD | -92.95% |
| 2006 FY | 1166.00 USD | -99.8% |
| 2006 Q3 | 59.87 Thousand USD | 13.98% |
| 2005 Q4 | 401.25 Thousand USD | 390.25% |
| 2005 FY | 590.13 Thousand USD | 2022.63% |
| 2005 Q1 | -6407.00 USD | 95.84% |
| 2005 Q2 | 113.44 Thousand USD | 1870.56% |
| 2005 Q3 | 81.84 Thousand USD | -27.85% |
| 2004 Q3 | 55.97 Thousand USD | -46.68% |
| 2004 Q1 | -37.79 Thousand USD | 64.65% |
| 2004 Q4 | -153.86 Thousand USD | -374.88% |
| 2004 FY | -30.69 Thousand USD | -164.33% |
| 2004 Q2 | 104.98 Thousand USD | 377.78% |
| 2003 FY | 47.71 Thousand USD | -69.47% |
| 2003 Q3 | 37.82 Thousand USD | -84.93% |
| 2003 Q4 | -106.91 Thousand USD | -382.66% |
| 2003 Q1 | -134.12 Thousand USD | 46.55% |
| 2003 Q2 | 250.9 Thousand USD | 287.08% |
| 2002 Q3 | 269.68 Thousand USD | -68.32% |
| 2002 Q1 | 738.22 Thousand USD | 134.97% |
| 2002 FY | 156.26 Thousand USD | 131.79% |
| 2002 Q4 | -250.92 Thousand USD | -193.05% |
| 2002 Q2 | 851.19 Thousand USD | 15.3% |
| 2001 Q1 | 737.19 Thousand USD | -7.77% |
| 2001 FY | 67.41 Thousand USD | -98.04% |
| 2001 Q4 | -2.11 Million USD | -411.28% |
| 2001 Q3 | 678.12 Thousand USD | -11.69% |
| 2001 Q2 | 767.92 Thousand USD | 4.17% |
| 2000 Q3 | 675.21 Thousand USD | -24.86% |
| 2000 Q1 | 883.57 Thousand USD | -50.29% |
| 2000 FY | 3.43 Million USD | -24.05% |
| 2000 Q2 | 898.59 Thousand USD | 1.7% |
| 2000 Q4 | 799.32 Thousand USD | 18.38% |
| 1999 Q4 | 1.77 Million USD | 116.05% |
| 1999 Q3 | 822.65 Thousand USD | 3.57% |
| 1999 Q2 | 794.28 Thousand USD | -27.89% |
| 1999 Q1 | 1.1 Million USD | 16.26% |
| 1999 FY | 4.51 Million USD | 48.52% |
| 1998 Q1 | 497.05 Thousand USD | 0.0% |
| 1998 FY | 3.04 Million USD | 67.78% |
| 1998 Q3 | 768.37 Thousand USD | 1.73% |
| 1998 Q2 | 755.33 Thousand USD | 51.96% |
| 1998 Q4 | 947.37 Thousand USD | 23.3% |
| 1997 FY | 1.81 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 100.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 100.0% |
| Nascent Biotech, Inc. | 2.22 Million USD | 100.0% |
| Rebus Holdings, Inc. | 664 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 100.0% |
| Qrons Inc. | 643.67 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 100.0% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | 13.54 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | 85.61 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 100.0% |
| Mesoblast Limited | 5.9 Million USD | 100.0% |
| Marizyme, Inc. | 19.23 Million USD | 100.0% |
| Genus plc | 147.7 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 100.0% |
| Pharming Group N.V. | 225.49 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 100.0% |
| ContraFect Corporation | 56.88 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 100.0% |
| IMV Inc. | 37.7 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 567.42 USD | 100.0% |
| ONE Bio Corp. | 6.44 Million USD | 100.0% |
| Accustem Sciences Inc. | 3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | 531.96 Thousand USD | 100.0% |
| Q BioMed Inc. | 3.43 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 100.0% |
| Biomind Labs Inc. | 994.18 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 100.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 100.0% |
| GB Sciences, Inc. | 1.42 Million USD | 100.0% |
| Alpha Cognition Inc. | 9.7 Million USD | 100.0% |
| HST Global, Inc. | 140.9 Thousand USD | 100.0% |
| CSL Limited | 3.44 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 100.0% |
| Halberd Corporation | 74.84 Thousand USD | 100.0% |
| Enzolytics Inc. | 2.17 Million USD | 100.0% |
| Agentix Corp. | 1.37 Million USD | 100.0% |
| Resverlogix Corp. | 12.71 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | 1.53 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 100.0% |
| AVAX Technologies, Inc. | 7.31 Million USD | 100.0% |
| Zenith Capital Corp. | 8.94 Million USD | 100.0% |
| Genscript Biotech Corporation | 825.34 Million USD | 100.0% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 100.0% |
| Kadimastem Ltd | 2.41 Million USD | 100.0% |
| Helix BioMedix, Inc. | 1.97 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 100.0% |
| BioStem Technologies, Inc. | 22.97 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 100.0% |
| LadRx Corporation | 3.81 Million USD | 100.0% |
| Cell Source, Inc. | 4.32 Million USD | 100.0% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 100.0% |
| NovAccess Global Inc. | 2.46 Million USD | 100.0% |
| Affymax, Inc. | 39.38 Million USD | 100.0% |
| Itoco Inc. | 919.14 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 100.0% |
| Mobile Lads Corp. | 554.54 Thousand USD | 100.0% |
| CytoDyn Inc. | 18.05 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 100.0% |
| SYBLEU INC | 160.87 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 100.0% |
| International Stem Cell Corporation | 5.27 Million USD | 100.0% |
| Bioxytran, Inc. | 3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 20.34 Thousand USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 36.26 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 735.83 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 100.0% |
| Neutra Corp. | 243.82 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 100.0% |
| PureTech Health plc | 144.59 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 100.0% |
| IXICO plc | 4.7 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 100.0% |
| CSL Limited | 3.89 Billion USD | 100.0% |
| Cellectis S.A. | 97.32 Million USD | 100.0% |